Table 1.

Trials in Coronary Angiogenesis

Multicenter Clinical Trial	Enrollment	Dates	Drug/Device	Outcome
AGENT	79	10/2001–11/2008	Ad5FGF-4	Results show evidence of favorable anti-ischemic effects with Ad5-FGF4 compared with placebo, and it appears to be safe. Angiogenic gene transfer with Ad5-FGF4 shows promise as a new therapeutic approach to the treatment of angina pectoris
FIRST	337	10 years	FGF-2	A single intracoronary infusion of rFGF2 does not improve exercise tolerance or myocardial perfusion but does show trends toward symptomatic improvement at 90 (but not 180) days
C-CURE	319	12/2008–1/2012	Mesenchymal stem cells	Cardiopoietic stem cell therapy was found feasible and safe with signs of benefit in chronic heart failure, meriting definitive clinical evaluation
CHART-1	484	11/2012–7/2017	Mesenchymal stem cells	Primary outcome neutral; exploratory analyses suggested a benefit of cell treatment on the primary composite in patients with baseline left ventricular end-diastolic volume 200–370 mL